Source: Fox News
Summary
A pro-life group, Students for Life of America, has threatened to sue the FDA over its failure to conduct environmental testing on the abortion drug mifepristone. The group claims the FDA violated the Endangered Species Act by not consulting wildlife agencies before approving the drug in 2000. The notice comes ahead of Dr. Heidi Overton’s Senate confirmation hearing to lead the FDA. SFLA President Kristan Hawkins said the FDA has 60 days to respond before a lawsuit is filed. The group has previously filed 11 petitions urging the agency to act.
Our Reading
As expected, the matter has reached another stage.
Students for Life files a notice of intent to sue the FDA.
Dr. Heidi Overton prepares for her confirmation hearing.
The group cites studies on mifepristone’s environmental impact.
Another legal challenge, another familiar script.
Author: Evan Null
Pro-Life Group Files Notice of Intent to Sue FDA
Students for Life of America has filed a notice of intent to sue the FDA over its handling of mifepristone. The group claims the agency failed to conduct required environmental testing. The notice was filed just hours before Dr. Heidi Overton’s Senate confirmation hearing. Overton is set to lead the FDA under the new administration.
Environmental Concerns and Legal Arguments
The group argues that the FDA violated the Endangered Species Act by not consulting wildlife agencies before approving mifepristone in 2000. They claim the drug may pose risks to waterways and wildlife. The notice includes six studies, though some do not directly test for mifepristone in water samples.
Statements from SFLA Leadership
SFLA President Kristan Hawkins said the FDA has 60 days to respond before a lawsuit is filed. She emphasized the need for the agency to follow the law. Hawkins also highlighted the importance of clean drinking water, saying it should be a concern for all Americans.
Previous Petitions and FDA Rejection
The group had previously filed 11 citizen petitions urging the FDA to act. In response to one of those petitions in January 2025, the FDA rejected SFLA’s legal argument. The agency stated that it was not required to consult with wildlife agencies before approving the drug.
Focus on New FDA Leadership
With new leadership at the FDA on the horizon, SFLA is reminding the agency of its responsibilities. Hawkins said the group wants the FDA to take the notice seriously. She also emphasized the need for accountability in the abortion industry and the government.
